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AbstrACt
Objectives To assess acceptability and feasibility of 
trial processes and the Rehabilitation Training (ReTrain) 
intervention including an assessment of intervention 
fidelity.
Design A two-group, assessor-blinded, randomised 
controlled trial with parallel mixed methods process and 
economic evaluations.
setting Community settings across two sites in Devon.
Participants Eligible participants were: 18 years old or 
over, with a diagnosis of stroke and with self-reported 
mobility issues, no contraindications to physical activity, 
discharged from National Health Service or any other 
formal rehabilitation programme at least 1 month before, 
willing to be randomised to either control or ReTrain and 
attend the training venue, possessing cognitive capacity 
and communication ability sufficient to participate. 
Participants were individually randomised (1:1) via a 
computer-generated randomisation sequence minimised 
for time since stroke and level of functional disability. Only 
outcome assessors independent of the research team 
were blinded to group allocation.
Interventions ReTrain comprised (1) an introductory one-
to-one session; (2) ten, twice-weekly group classes with 
up to two trainers and eight clients; (3) a closing  
one-to-one session, followed by three drop-in sessions 
over the subsequent 3 months. Participants received a 
bespoke home-based training programme. All participants 
received treatment as usual. The control group received an 
exercise after stroke advice booklet.
Outcome measures Candidate primary outcomes 
included functional mobility and physical activity.
results Forty-five participants were randomised 
(ReTrain=23; Control=22); data were available from 
40 participants at 6 months of follow-up (ReTrain=21; 
Control=19) and 41 at 9 months of follow-up (ReTrain=21; 
Control=20). We demonstrated ability to recruit and 
retain participants. Participants were not burdened by 
the requirements of the study. We were able to calculate 
sample estimates for candidate primary outcomes and test 
procedures for process and health economic evaluations.
Conclusions All objectives were fulfilled and indicated 
that a definitive trial of ReTrain is feasible and acceptable.
trial registration number NCT02429180; Results.
IntrODuCtIOn  
Five years after initial stroke, one in three 
individuals have residual physical impair-
ment,1 equating to over 300 000 individuals 
in the UK living with disability from stroke.2 
Provision of stroke rehabilitation is typi-
cally front loaded, with resources focused 
on in-patient care and early supported 
discharge. Support tapers off after a few 
months,3 with many individuals reporting 
unmet long-term needs 4 
The National clinical guideline for stroke 
advise for secondary prevention that stroke 
survivors engage in 150 min of physical 
activity a week, in bouts of 10 min or more, 
starting light and developing across time 
to moderate levels of intensity.5 However, 
many stroke survivors do not meet these 
recommendations6 7 due to combinations 
of personal (eg, physical or psychological 
strengths and limitations of this study
 ► A community-based exercise intervention after 
stroke developed with service users.
 ► A pilot randomised trial developed following 
Medical Research Council guidelines on complex 
interventions.
 ► Mixed-method approach for answering feasibility 
and acceptability objectives.
 ► Objective physical activity capture via accelerometry 
but subjective self-report outcomes for functional 
mobility and psychosocial measurements.
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impairments) and environmental factors (eg, lack of 
programmes and facilities). To address this problem, 
community-based programmes are promoted.8–10 These 
tend to focus on cardiovascular fitness with less emphasis 
on functional improvements or on promoting on-going 
exercise self-management. National stroke guidelines5 
identify the importance of interventions for functional 
improvement11 and self-management,12 but evidence is 
lacking regarding these types of intervention.13
Action for Rehabilitation following Neurological 
Injury (ARNI) is an approach aimed at improving 
function and facilitating self-management14 and has a 
detailed self-help book. The ARNI approach embodies 
a set of principles (eg, instilling a commitment to 
regular exercise) and techniques tailored to individual 
need. The ARNI Institute trains registered exercise 
professionals to deliver key ARNI techniques. Clinical 
Commissioning Groups (CCGs), charitable and local 
authorities have started to provide community-based 
ARNI training for stroke survivors, which has been posi-
tively received by participants, carers and practitioners15; 
however, there is currently no randomised controlled 
trial (RCT) evidence for evaluating its impact on stroke 
outcomes or its cost-effectiveness.
background and objectives
Using the Medical Research Council’s framework for the 
development and evaluation of complex interventions16 
and considerable Patient and Public Involvement, we 
have designed a testable programme called Rehabil-
itation Training (ReTrain).17–20 ReTrain is a commu-
nity-based, manualised group programme combining 
ARNI principles and key techniques with best practice 
guidelines for stroke.9 17 The overall aim of our pilot 
RCT was to inform the design and delivery of a defini-
tive RCT. Our objectives were to (1) assess feasibility and 
acceptability of recruitment (target n=48), randomisa-
tion, allocation concealment and outcome assessment 
blinding; (2) determine retention rates (target of <20% 
attrition); (3) check ReTrain’s acceptability and feasi-
bility for participants, and refine the trainer manual; 
(4) test candidate outcome measures, assess their 
burden, levels of completion and estimate outcome 
variance (to inform definitive trial sample size); 
(5) perform process evaluation including intervention 
fidelity assessment and (6) calculate ReTrain costs and 
assess feasibility of collecting health and social service 
resource use.
MethODs
A brief methods overview is provided in accordance 
with guidance for reporting pilot trials21; further details 
are available in the published protocol.22 Ethics review 
was conducted by National Research Ethics Service 
Committee South West Cornwall & Plymouth (REC Ref: 
15/SW/04).
trial design
ReTrain was a two-group, assessor-blinded, randomised 
controlled external pilot trial with parallel mixed 
methods process and economic evaluations. Eligible 
participants were individually randomised 1:1 to 
intervention (ReTrain) or control (exercise advice 
booklet23).
Participants
Inclusion criteria were as follows: (1) diagnosis of 
stroke; (2) any time since stroke but at least 1 month 
since discharge from National Health Service (NHS) 
physical rehabilitation services; (3) able to walk inde-
pendently indoors with or without mobility aids, but 
with self-reported difficulty with stairs, slopes or uneven 
surfaces; (4) willingness to be randomised and attend 
the training venue and (5) cognitive capacity and 
communication ability sufficient to participate.
Exclusion criteria were less than 18 years old, currently 
(or within 1 month of) receiving ARNI training or 
have contraindications to moderate to vigorous phys-
ical activity (adapted from American College of Sports 
Medicine guidelines24). Participants were recruited 
from two CCGs. Participants were identified by: 
(1) clinicians in NHS primary care, hospital and commu-
nity stroke services; (2) contacts in the local Clinical 
Research Network and Clinical Research Facility; 
(3) promotion via local stroke support networks (eg, 
Stroke Association) and (4) word of mouth, study flyers 
and adverts.
Intervention
ReTrain aims to: (1) enhance function through task-re-
lated practice, teaching compensatory techniques 
and providing targeted strength training (cardiovas-
cular fitness gains also occur through these activities); 
(2) develop self-management skills for on-going reha-
bilitation; (3) deliver personalised training using nego-
tiated goals and (4) instil a commitment to regular 
exercise for health improvement and longer-term 
maintenance. ReTrain facilitates safe and efficient prac-
tice of walking in varied terrains, kerbs, cambers and 
in crowds, turning and moving quickly, climbing steps 
and stairs without rails, getting to and from the floor 
without furniture or other aids and moving without 
mobility aids or while carrying loads. Training is based 
on a manual and led by personal trainers on the UK 
Register of Exercise Professionals (level 3 or above) 
who are ARNI-trained and accredited and have had 
additional training in the delivery of ReTrain. There 
was a maximum ratio of one trainer to four stroke survi-
vors. ReTrain was delivered in a community setting (one 
gym, two church halls and one community centre) with 
twice-weekly 2-hour sessions over 3 months, comprising: 
an introductory one-to-one session (home visit); 10, 
twice-weekly group classes with up to 2 trainers and 8 
clients (training venue); a closing one-to-one session 
(home visit); followed by 3 (one  per month) drop-in 
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sessions. Participants completed bespoke home-based 
training (homework) throughout.
Control
All participants received treatment as usual. This 
ranged from zero treatment to engagement with any 
health service(s). We requested that all trial partici-
pants did not participate in additional physical rehabili-
tation (either NHS or private) but we could not prevent 
them from doing so. We did not monitor control group 
participation in any treatments during the trial but did 
record health service use at the end of the trial for all 
participants. The control group also received an advice 
booklet about exercise after stroke.23
Outcomes
Feasibility, acceptability and process outcome: numbers and 
details of those approached; recruitment and retention 
figures.
Acceptability of randomisation, outcome measurement 
burden and the intervention: completion of question-
naires and objective assessments, interviews with 10 
intervention and 10 control group members and the 
trainers. Safety: Adverse events25 identified via trainer 
and ReTrain participants (during the programme) and 
participant reports (all participants during 6-month 
and 9-month assessments).
Intervention fidelity: attendance registers, accelerom-
etry, exercise ‘homework’ diaries, trainer completed 
session checklists and video analysis of (early, middle 
and late programme) training sessions.
We tested a range of candidate primary and secondary 
outcome measures.
Primary outcomes: Rivermead Mobility Index,26 27Timed 
Up and Go Test,28 modified Patient-Specific Functional 
Scale,29 7-day objective physical activity levels using 
wrist-worn accelerometry (GENEActiv, Activinsights, 
Kimbolton, Cambridge UK) and a physical activity diary.
Secondary outcomes: Stroke Self-Efficacy Question-
naire,30 Fatigue Assessment Scale,31 32 Exercise Beliefs 
and Exercise Self-Efficacy questionnaires,33 SF12,34 
EQ-5D-5L,35 Stroke Quality of Life (QoL) question-
naires,36 Carer Burden Index37 and Health and Social 
Service use through a Service Receipt Inventory.38
Physical outcome baseline assessments (completed 
by research team) and follow-up assessments (at 6 
and 9 months, completed by blinded assessor) were 
conducted in the participant’s home. Researchers 
visited participants to fit the accelerometer, drop-off 
questionnaires and diary 1 week prior to blind assessor 
visits. Assessors administered primary outcome physical 
measures and collected accelerometers, questionnaires 
and diaries.
sample size
We required 48 participants (24 per group) as (1) 30 
complete data sets are recommended for pilot studies 
to estimate outcome variance39 and (2) we wanted to 
investigate variations in context by running the inter-
vention three times (ie, 3×8 patients). This number also 
allowed estimation of a predicted attrition rate of 20% 
with a precision of ±5% with 95% certainty.
randomisation and blinding
The random sequence was computer generated with mini-
misation for time since stroke (≤ 3 months vs > 3 months) 
and level of functional disability (modified Rankin 
Scale (mRS)40 score ≤ 2 vs > 2). Allocation concealment 
was ensured by using a password protected validated 
web-based remote randomisation service supported by 
the Peninsula Clinical Trials Unit. The Trial Manager 
requested randomisation only after a cohort of partici-
pants had been consented.
Participants, trainers providing the intervention and 
researchers conducting the process and economic eval-
uations could not be blinded to allocation. However, 
outcomes were assessed by independent researchers 
(not based at research centre) who were blinded to 
group allocation. Participants were reminded not to 
reveal their allocation to assessors but any unblinding 
was recorded; after assessments assessors were asked to 
guess participant allocation.
Data analysis
Analysis was primarily descriptive with participant flow 
summarised and estimates of screening, recruitment and 
attrition reported. Means and SD for all outcomes are 
reported at baseline, 6-month and 9-month follow-up for 
each group.
Intervention fidelity was assessed using mixed 
methods: qualitative video analysis comparing the 
trainer manual standard versus observed technique 
(two researchers independently assessed videos) 
combined with interview data and summary scores from 
trainer completed session checklists. Qualitative data 
were manually analysed descriptively and with content 
analysis for trial processes; additional thematic analysis 
was used for interview data. One person (MN) led the 
qualitative analysis but this was then discussed (MN 
and SGD), checked (RC) and agreed (MN, SGD, LP 
and RC).
We used a micro-costing approach to calculate costs 
associated with ReTrain: staff time (trainers, adminis-
trator and facilitators), venue hire, training equipment 
(annualised over time), course materials, consum-
ables and travel costs (participants, trainers and facil-
itators). The costs of the intervention were estimated 
as a cost per programme and a cost per participant. 
The estimated costs of the intervention per participant 
were based on the number of participants enrolled 
on the programme. The base case scenario assumed 
the average number of participants per programme 
across all cohorts. Sensitivity analyses were conducted 
using the minimum and maximum number of partici-
pants enrolled for the programme and the quantity of 
programme materials that were wasted. We analysed the 
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relative benefits of calculating health-related QoL using 
SF-6D (developed from the SF-12) over the Quality-Ad-
justed Life Year (QALY) calculated (using EQ-5D 5 L) 
from the baseline measures.
Sample size estimates for a definitive trial were calcu-
lated for candidate primary outcomes using the SD 
observed in this pilot population and published minimal 
clinical important difference (MCID) at 90% power 
and 5% alpha, and assuming 20% attrition. Where 
no published MCID could be sourced, we assumed a 
small to moderate effect size of 0.4 of a SD.41 The trial 
statistician undertook calculations using the ‘samspi’ 
command in STATA V.14.2
results
Recruitment took place from June 2015 to January 2016. 
The intervention ran in four cohorts, participant flows 
are shown for each (figure 1) and for the trial overall 
(figure 2). Initial recruitment was slow so to prevent late 
running of the trial we split the first cohort. Six-month 
follow-up outcome assessments took place in January to 
July 2016 and 9-month follow-up in April to October 2016.
Objective 1: Assess the feasibility and acceptability of 
recruitment, randomisation, allocation concealment and 
processes for outcome assessment and blinding
We screened 115 individuals to recruit 50 participants 
(figure 1) in 8 months (2 months ahead of schedule). 
Of these, 45 (90%) were randomised (figures 1 and 2). 
Five individuals withdrew prior to randomisation due 
to ill health or the time lag between agreeing to take 
part and a cohort being ready to randomise. Table 1 
shows baseline characteristics of those randomised, 
indicating a balance of characteristics across 
trial arms.
Blinding of outcome assessors was considered 
successful as only 2/41 (5%) participants revealed their 
allocations after completion of outcome measures, both 
were intervention participants. Different assessors were 
used for subsequent assessments therefore risk of bias was 
minimised.
Objective 2: Acquire retention rates and outcome variance
Forty out of 45 (88%, 95% CI: 76% to 96%) completed 
6-month and 9-month follow-ups. Despite fewer people 
being randomised than expected, high retention 
preserved the number of datasets needed to perform our 
sample size estimates (table 2).
Objective 3:  Check ReTrain’s acceptability and feasibility for 
participants and refine the trainer manual
Eleven themes from 20 qualitative interviews summarise 
participants’ views, box 1 provides illustrative quotes.
1. Study information: Participants considered informa-
tion received as adequate. Five noted that information 
was limited, but most were unconcerned. Two added 
that too much information may have been detrimen-
tal to recruitment. Four others were satisfied with the 
information they received.
2. Outcome measure burden: Participants found the 
assessment process acceptable. Fifteen indicated no 
burden. Three participants indicated that they need-
ed help from their carers to complete questionnaires, 
particularly recalling and reporting health resource 
use, placing a time burden on their carer.
Figure 1 Recruitment and randomisation by cohort.
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3. Venue: Half of the ReTrain participants were very 
positive about the training venues. Important fea-
tures were space, provision of fluids (water and tea) 
and easy availability of parking. For some the travel-
ling distance was a concern; two noted their venue (a 
gym) was very noisy, insufficiently heated and the ses-
sion time was too early. Some noted the small amount 
of equipment as an advantage (it aided transfer of 
exercises to their home), whereas others felt that the 
equipment was not sufficiently specialist.
4. Adherence to ReTrain (see also Objective 5): All 10 
ReTrain interviewees reported training in the 5 core 
(ARNI) techniques. Homework was discussed by all 
but lacked specificity, only two had clear homework 
examples that were effectively incorporated into 
their training. Although goal setting was a core el-
ement, only four specifically identified how their 
goals were linked into their overall programme. 
Three participants reported not attending drop-in 
sessions due to lack of information. Of three who 
attended, two suggested the drop-ins repeated pre-
vious sessions.
5. Group dynamics: Group working was positively re-
garded and seen as integral to programme effective-
ness. There were exceptions, one participant did not 
find ‘performing’ in public a positive experience. 
Likewise some suggested that groups reduced train-
ing intensity relative to one-to-one training.
Figure 2 Participant flow through the trial.
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6. Comorbidities: Participants identified several comor-
bidities, such as knee replacements, cancer, angina, 
diabetes, amputation and depression. These had po-
tential to impact both the training and research par-
ticipation but for most any concerns were accommo-
dated by trainers. However, in one case, some uncom-
fortable discussions occurred before an appropriate 
Table 1 Baseline participant demographics
ReTrain
(n=23)
Control 
(n=22)
Gender, n
  Male (%) 16 (70) 14 (67)
  Age, years, mean (SD) 70 (12) 71 (10)
Age category, years (n=45), n (%)
  <45 1 (4) 0
  46–50 0 (0) 1 (5)
  51–60 3 (13) 2 (9)
  61–70 10 (43) 6 (27)
  71–80 5 (22) 8 (36)
  81–90 2 (9) 5 (23)
  90+ 2 (9) 0 (0)
Time since stroke, months, n (%)
  <12 3 (13) 3 (14)
  12–24 4 (17) 4 (18)
  25–48 5 (22) 5 (23)
  49–72 2 (9) 5 (23)
  73–96 4 (17) 2 (9)
  97+ 5 (22) 3 (14)
Time since stroke minimisation categories, months, n (%)
  ≤3 1 (4) 0 (0)
  >3 22 (96) 22 (100)
Type of stroke, n (%)
  Haemorrhagic 3 (13) 1 (5)
  Ischaemic 15 (65) 15 (68)
  Both 0 (0) 1 (5)
  Missing 5 (22) 5 (23)
Stroke rehabilitation, weeks
  n 21 21
  Average no of weeks (SD) 8 (9) 14 (19)
  Median no of weeks 6 12
  Range 0–32 0–88
  Unknown length rehab, n 2 1
Functional disability (sMRS), n (%)
  0 1 (4) 0 (0)
  1 2 (9) 1 (5)
  2 4 (17) 9 (41)
  3 16 (70) 12 (55)
sMRS minimisation categories, n (%)
  ≤2 7 (30) 10 (45)
  >2 16 (70) 12 (55)
Comorbidities,* n (%)
  Hypertension 18 (78) 18 (82)
  Type 2 diabetes mellitus 4 (17) 4 (18)
  Depression 8 (35) 5 (23)
Continued
ReTrain
(n=23)
Control 
(n=22)
 Chronic kidney disease 2 (9) 1 (4)
 Asthma/COPD 4 (17) 3 (14)
 Other 5 (22) 3 (14)
Medications,* n (%)
 Diuretics 3 (13) 1 (5)
 Anticoagulants 8 (35) 10 (45)
 Antiplatelet 15 (65) 12 (55)
Antihypertensives
  Calcium channel blockers 6 (26) 14 (64)
  ACE inhibitors 13 (57) 8 (36)
  Other 9 (39) 7 (32)
 Statins (%) 18 (78) 19 (86)
 Antidepressants (%) 8 (35) 5 (23)
 Diabetes medication (%) 4 (17) 4 (18)
 Chronic pain medication (%) 12 (52) 8 (36)
 Other (%) 5 (22) 3 (14)
Employment status, n (%)
 Employed (and working) 2 (9) 1 (5)
 Retired 18 (78) 15 (68)
 Semiretired 1 (4) 0 (0)
 Unemployed 2 (9) 5 (27)
Prestroke exercise history, n
 Exerciser (%) 10 (43) 8 (36)
MMSE
 n 22,† 22
 Mean (SD) 27.5 (2.54) 27.9 (3.01)
 Median 28 29
 Range 19–30‡ 19–30‡
*Participants may have more than one comorbidity/
medication.
†One participant with severe aphasia had difficulties 
completing the MMSE. The participant could understand 
and follow instructions and was considered cognitively able 
to participate in the trial.
‡Higher scores indicate better cognitive function. 
Participants range from no to moderate degree of cognitive 
impairment.
ACE, angiotensin-converting enzyme; COPD, Chronic 
obstructive pulmonary disease; MMSE, Mini–mental state 
examination; ReTrain, Rehabilitation Training; sMRS, 
Simplified Modified Rankin Scale score. 
Table 1 Continued 
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balance of perceived capability and training challeng-
es was reached. Three participants with visual deficits, 
dyslexia and dysgraphia mentioned difficulties in 
completing the research documents.
7. Carer health: Two ReTrain participants commented 
on how commitment to the programme impacted 
their partner’s health: one stopped attending sessions 
because the time away resulted in excessive strain on 
his wife; another expressed similar concern but did 
not stop attending.
8. Trainer manual: we refined the trainer manual 
throughout the study. Issues raised during inter-
views guided revisions including greater emphasis 
and clarification about use of goal setting, drop-ins, 
homework diaries and managing participants with 
comorbidities.
Objective 4: Assess outcome completion and burden
We collected baseline (n=41), 6-month (n=40) and 
9-month (n=41) follow-up data on the majority of partic-
ipants (figure 2). Accelerometry wear time (24 hours 
for 7 days) was high, most having 6 or more valid days 
(≥16 hours per day, including ≥1 weekend day). Only 
two participants at baseline, one at 6 months and three 
at 9 months did not achieve 4 valid days of wear time. 
There was very little missing data. For three primary 
outcome measures, there was only one participant 
with missing data at any given assessment time-point. 
For secondary outcomes, there was either no missing 
data or only one to two participants with missing 
data at each time-point, apart from the exercise diary 
(between two and four participants with missing data 
at each time-point) and the service receipt inventory 
(between three and seven participants with missing 
data). There were eight participants without accel-
erometer data at 9-month assessment owing to hard-
ware (device) and software (data extraction method) 
malfunctions.
Objective 5:  Perform process evaluation with an assessment 
of intervention fidelity
We implemented a comprehensive video recording 
schedule (over 200 recordings) to capture participant 
and trainer adherence to key ARNI techniques. Both 
trainers and participants demonstrated high adher-
ence. Modifications to techniques (to accommodate 
participant comorbidities) were captured and informed 
trainer manual development.
We combined metrics from attendance registers and 
homework records to generate a ‘dose’/adherence 
score, categorising individuals into low (<50%), medium 
(50%–75%) and high (>75%) adherence categories. Of 
23 ReTrain participants, 2 did not receive the interven-
tion (1 returned to work; 1 withdrew from the study), 5 
had low adherence, 5 medium adherence and 11 high 
adherence. These latter 16 (70%) were considered to 
have received sufficient ‘dose’ of ReTrain.
Trainers varied in their completion of session check-
lists: pre-exercise and end-of-session components 
were less consistently reported compared with ARNI 
techniques but overall there was good adherence to 
programme delivery.
Objective 6: Calculate the cost of intervention delivery and 
feasibility of collecting health and social service resource use
ReTrain costs were generated for each cohort, 
accounting for different programme sizes (four or 
eight participants) and venues. Costs per participant 
ranged from £615 to £972. The total per participant 
cost for ReTrain (assuming 24 participants) was £777. 
We conducted medical notes review on 35/41 partici-
pants and compared this ‘gold standard’ with self-re-
ported health resource use. Participants reported 
using fewer resources compared with case notes 
review. Data from medical notes informed the cost–
utility and effectiveness frameworks for use in a defin-
itive trial.
Table 2 Sample estimates for potential candidate primary outcomes from ReTrain pilot RCT
Primary outcome measure Sample size estimates* MCID Observed SD range
Effect size 
(MCID/SD)
Rivermead Mobility Index 36–44 3.0† 2.33–2.66 1.13–1.29
Timed Up and Go 1438–2673 1.2 – 3.4‡ 15.69–21.39 0.06–0.22
Modified Patient-Specific Functional Scale 16–200 1.0 – 3.0‡ 1.58–1.94 0.52–1.7
PA (accelerometer) 350–1458 Not available Not applicable 0.2–0.45§
*Figures represent overall (two groups) sample size estimates required for a definitive trial. Sample sizes estimated for 1:1 allocation at 90% 
power and 5% alpha and assuming 20% attrition. Calculations are conservative showing range from best case scenario (largest MCID and 
smallest SD) to worst case scenario (smallest MCID and largest SD) of SDs observed in this trial and published MCIDs where available.
†MCID available from stroke research for the Rivermead Mobility Index (http://www.strokengine.ca/psycho/rmi_psycho/).
‡MCIDs identified from other disease groups used as proxies as no published stroke MCIDs.47 48
§There are no MCID data available for PA (accelerometry) in stroke (or any other cardio vascular disease), we therefore applied sample size 
calculations undertaken for a relevant ongoing HTA NIHR trial, which estimated n=562 (effect size 0.3) or n=413 (effect size 0.35) (http://www.
isrctn.com/ISRCTN15644451).
HTA NIHR, Health Technology Assessment, National Institute of Health Research; MCID, minimal clinical important difference; PA, physical 
activity; RCT, randomised controlled trial; ReTrain, rehabilitation training.
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Descriptive analysis of participant outcomes
Table 3A,B report number, mean scores and SDs 
across, respectively, candidate primary and secondary 
outcome measures at each time point of the pilot trial. 
The trial was not powered to detect differences in 
outcome between trial arms or over time and so we 
do not interpret the patterns of means. However, the 
results clearly demonstrate that we were able to collect 
the necessary data and retained acceptable comple-
tion rates on all measures across all time points of the 
study. Attrition was lower than the 20% expected. For 
each outcome measure (except carer burden as not 
everyone had a carer), we achieved in excess of the 
30 cases (ie, 15 completed measurements per arm) 
recommended for pilot studies to estimate outcome 
variance.
safety
During assessment periods, there was one serious but 
unrelated event in the intervention group (none in the 
control group) and slightly fewer overall adverse events 
in the intervention group (table 4A).
For ReTrain only (table 4B), there were six serious 
adverse events during the intervention period: four 
were unrelated, one possibly related (fainted) and one 
probably related (TIA) to the intervention. Of the 22 
adverse events reported, 3 of them occurred at the 
venue (one x fall; one x trip; one x ankle strain).
DIsCussIOn
The ReTrain pilot trial met all its prestated feasibility 
objectives: the intervention, trial design and research 
box 1 Participant quotes from qualitative interviews
Acceptability
“It is ten weeks, you do it twice a week. Personally for the first say three or four weeks, I’d think well this is getting me nowhere, but then you think 
that you notice things, things are improving and at the end of ten weeks you want to go for twenty weeks” (4; 119–125).
 
“I’d tell them [another stroke survivor] to go ahead and do it and to take it step by step and not to worry about it. Because you are treated with great 
respect, it was wonderful and they were. I’ll never be able to speak highly enough of them.” (25; 388–390).
Intervention approach
“It opened my eyes to what can be done you know. How can I put it? It wasn’t as if I believed that I couldn’t do something it was being pointed in the 
right direction…heh I can do it……Great you’ve done it, you did it and you do it again. Yeah it was great” (4; 358–361).
 
“It wasn’t easy at first, but I used to manage it” (5; 246).
 
“It was the way they addressed how you do your exercises. What it is doing to you and all the rest of it. Now to me that was absolutely important, 
because it made sense of why you are doing all this pumping up and down, and if you can’t do that, do this” (22; 252–255).
 
“It was you felt as if you were a human being with them. You know and you were treated with respect…and although you couldn’t do things and you 
felt a bit of an idiot, they never let you feel like that” (25; 567–572).
 
“It’s a bit like playing scales…it’s not creative but as I gradually realise it, it could potentially be creative…doing something that I had been doing 
without thinking before and now couldn’t. …Now and again I walk without my stick without realising it, that’s creative I think” (6; 354–392).
Impact of programme: psychologically
“I suppose it is attitude of mind as much as anything. I mean I felt I’d gone through that stage of training and that I was going to get better. It built my 
spirit up…I felt as if it, well it was worth the three months you know and at the end of the day I hope I’m going to get back to something like normal” 
(16; 358–365).
 
“It really helped me mentally, you know I thought right I can do this because before I was going into my shell, thinking I can’t do this and I can’t do 
that. Oh I am not going out. Then I went on that [ReTrain] and it gave me an element of confidence” (43; 562–565).
Impact of programme: physically
“You started to notice they are actually starting to fall into place. I don’t remember doing that last time. But I am doing it now great get on with it I am 
doing it faster now” (4; 189–190).
 
“I know if I went down which I did one day in the hall in the early stages of coming back home and I did manage to get up and walk upstairs…but I 
wouldn’t have been able to do that had I not had that [training]” (16; 475–477).
homework adherence
“Trainers were always on about doings exercises at home…I could never pin him down to how long that should be for though” (6; 624).
Programme technique adherence
“I think that was the big thing you saw the benefits after the second, well the first or second session we had.’ ‘Oh we can do.”
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processes were acceptable to participants as well as 
feasible and safe to deliver; we demonstrated feasibility of 
recruitment (recruiting above our target of 48) and reten-
tion (<20% attrition). At the point of randomisation, we 
were slightly under target (45/48). However, due to high 
retention, we preserved the number of datasets required 
(30) to calculate sample size estimates. Furthermore, 
participants were not unduly burdened by study require-
ments and there were high completion rates for most 
outcome measures. We also successfully rehearsed proce-
dures for process and health economic evaluations as 
well as trial governance processes (trial management and 
independent trial steering meetings) and maintained our 
strong Patient and Public Involvement. Participant inter-
views, outcome measurement results and fidelity assess-
ments highlighted refinements that we have already, or 
can, put in place for a future definitive RCT of ReTrain. 
For example, we have some new insights into how to 
enhance delivery by trainers and engagement by partici-
pants (eg, by placing more focus on individually tailored 
goal setting; stressing goal and homework reviews; better 
explanation and promotion of the drop-in sessions). 
These are all relatively small amendments that are likely 
to enhance the impact of the training programme. Our 
trial compares favourably with another feasibility RCT 
assessing the delivery of the Bridges stroke self-manage-
ment programme,42 which had relatively low recruitment, 
questions regarding programme delivery in addition to 
usual rehabilitation and recommendations for further 
assessment of intervention fidelity. Some of their findings 
were similar to ReTrain: participants were broadly posi-
tive about their programme; health professionals found 
it acceptable to use and researchers noted the lack of 
outcome measure sensitivity for detecting change.42
limitations and lessons for planning design of a future trial
When planning this study we selected our candidate 
primary outcome measures on the basis that they were 
likely to measure improvements that could be attributed 
to our intervention; our pilot work was therefore to 
determine acceptability and feasibility (including their 
psychometric utility) of these measures. However, we 
were not able to identify a clear candidate primary 
outcome for a definitive RCT from this pilot work. It 
is possible that an ‘activities of daily living’ measure (as 
typically used in rehabilitation studies) may be more 
useful in a future definitive trial. Identifying robust 
outcome measures in rehabilitation trials is a common 
problem,43 compounded by variability in stroke-related 
disability and participants’ comorbidities. This pilot 
trial was not designed (statistically powered) to test 
for differences between treatment arms, so no inferen-
tial analyses were performed. Any perceived trend (or 
absence of a trend) should not be interpreted as an indi-
cation of an effect (or its absence) and outcomes should 
not be selected based on any assumed trend. Accept-
ability outcomes coupled with a pragmatic and effi-
cient (cost-effective) trial design better inform choice 
Table 4A Adverse Events and Serious Adverse Events reported during 6-month and 9-month outcome assessment periods 
for both ReTrain and control groups
Event type Total events
Attribution No of people 
reporting 
eventRelated Probably related Possible related Unrelated
ReTrain (n=21) AE 125* 6 5 73 41 19
SAE 1† 0 0 0 1 1
Control (n=20) AE 150‡ 0 0 0 150 19
SAE 0 0 0 0 0 0
*Muscle soreness (n=26), fatigue (n=58), falls (n=12), trips (n=10) and other (n=19; including but not limited to: low mood, itchiness, colds, 
issues with eyesight and cystitis).
†Ambulance conveyance to A&E due to reaction to antibiotics being taken for chest infection.
‡Muscle soreness (n=39), fatigue (n=50), falls (n=19), trips (n=12) and other (n=30; including but not limited to: low mood, depression, dizzy 
spells, sore toes, poor memory, colds, poor sleep, loss of sense of smell and issues with eyesight).
AE, adverse events; ReTrain, rehabilitation training; SAE, serious adverse events.
Table 4B Adverse Events and Serious Adverse Events reported during ReTrain programme
Event type Total events
Attribution No of people 
reporting eventRelated Probably related Possible related Unrelated
ReTrain (n=21) AE 2* 7 0 12 3 11
SAE 6† 0 1 1 4 5
*Muscle soreness (n=0), fatigue (n=2), falls (n=10), trips (n=1) and other (n=9; including but not limited to: fainting; twisted or swollen ankle and 
suspected TIA (non-confirmed)).
†Urine retention (n=3), black-out/fainted (n=1), renal and heart failure (n=1) and TIA (n=1).
AE, adverse events; ReTrain, rehabilitation training, SAE, serious adverse events; TIA, Transient Ischaemic Attack.
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Open Access
of outcome. From our sample, the Timed Up and Go 
task would be unsuitable due to potentially large sample 
size requirements (~2000 participants) and the base-
line high levels of mobility meant that the Rivermead 
Mobility Index demonstrated a ceiling effect, so could 
only be used if we altered inclusion criteria. Physical 
activity was measured robustly via accelerometry and 
may be the best candidate. We had some software and 
hardware malfunctions but important lessons have been 
learned to mitigate these problems in future. Capture 
of frequency and intensity of activity would allow 
comparison with stroke guidelines. Although there is a 
cost implication, accelerometry provides a more objec-
tive measurement of daily activity and may also be an 
adequate proxy of functional mobility; however, we will 
also investigate the benefits of using other PA measures 
such as questionnaires (instead of our diaries) or using 
multiple measures such as accelerometry and heart rate 
monitors while being aware of problems with compli-
ance and participant burden.44
Further limitations relate to the lack of valida-
tion of our adherence measure and the local demo-
graphics: our sample did not have a wide age range 
or ethnic diversity. While we did demonstrate delivery 
in different locations in the South West, our plans for 
a larger definitive trial would include a wider demo-
graphic from more centres across the UK.
For a future trial, we plan to implement more read-
able, higher quality written (and pictorial) infor-
mation and questionnaires although the amount of 
information provided was appropriate. We will miti-
gate recruitment loss prior to randomisation by estab-
lishing expression of interest and eligibility to take 
part but delaying taking consent until we are confi-
dent of sufficient numbers to create a cohort for 
randomisation; this has resource implications that 
will need to be built into future funding. We will run 
ReTrain in community centres or halls as these were 
more acceptable and much cheaper than gyms; we will 
provide a more detailed ReTrain induction to ensure 
trainers understand and communicate all components 
of the programme. For the QALY comparisons, recent 
policy changes mean the conversion from SF-12 to 
SF-6D has been phased out, and so less justification 
for using the SF-12 in a future study. Instead we will 
consider using the Stroke Impact Scale (SIS) as this 
is a valid health-related QoL measure. This may also 
be a better candidate self-report primary outcome 
measure for a definitive trial as it has shown sensi-
tivity in long-term stroke survivors who have mild to 
moderate stroke.45 The SIS assesses multiple facets of 
physical and emotional issues and so would align with 
perceived physical and psychological benefits partici-
pants attribute to ReTrain. Our sample size estimates 
for candidate objective primary outcomes (table 2) 
indicate that we will need a moderately sized trial 
(n=562, effect size 0.3 or n=413, effect size 0.35) for 
PA assessed by accelerometry or a smaller trial (n=96) 
if we use the physical component domain of the SIS 
(based on 80% power, 5% alpha and assuming 20% 
attrition46). We have established appropriate process 
evaluation methods to capture multiple facets of 
intervention fidelity.
Generalisability
This pilot study was not designed to demonstrate gener-
alisability; however, our participant population repre-
sent the subset of community-dwelling stroke survivors 
who have some independent mobility but remain with 
stroke-related disability that affects their QoL. Our 
participants also represent the growing proportion of 
people who have more than one long-term condition. 
ReTrain techniques target the effects of stroke but can 
accommodate other conditions which trainers take into 
account when preparing the participant’s individually 
tailored programme. Some of the key ReTrain (ARNI-
based) techniques are designed for people with unilat-
eral impairment, such as hemiparesis; however, one of 
our participant’s main unilateral impairment was due 
to diabetes-related lower limb amputation, illustrating 
how ReTrain can accommodate people with multiple 
comorbidities.
COnClusIOn
Our pilot trial has demonstrated that ReTrain is 
feasible, acceptable and safe. We met our recruitment 
and retention targets and demonstrated our ability to 
run our intervention in different locations. Participants 
were not unduly burdened by study requirements and 
most outcome measures had high levels of comple-
tion. We successfully tested procedures for process and 
health economic evaluations. Participant interviews, 
outcome measurement results and fidelity assessments 
highlighted some issues needing refinement prior to a 
future definitive RCT of ReTrain. Many of these have 
already been addressed and we intend to seek funding 
for a definitive trial.
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